Burden of pediatric hepatitis C

World Journal of Gastroenterology

Volumn 19, Issue 44, 2013, Pages 7880-7888

  El Shabrawi, Mortada Hassan ^a   Alanani, Naglaa Mohamed Kamal ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Burden; Cost; Genotypes; Hepatitis C virus; Pediatrics

Indexed keywords

ANTIVIRUS AGENT; BI 207127; BOCEPREVIR; DANOPREVIR; FALDAPREVIR; INTERLEUKIN 28B; LEDIPASVIR; MERICITABINE; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NONSTRUCTURAL PROTEIN 5B POLYMERASE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; RITONAVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VEDROPREVIR;

ARTICLE; COMORBIDITY; CRYOGLOBULINEMIA; GENOTYPE; HEALTH CARE COST; HEALTH EDUCATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; QUALITY OF LIFE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW (TOPIC); VIRUS TRANSMISSION;

BURDEN; COST; GENOTYPES; HEPATITIS C VIRUS; PEDIATRICS;

ADOLESCENT; AGE FACTORS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; DEVELOPING COUNTRIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INFANT; INFANT, NEWBORN; MALE; PREVALENCE; PROGNOSIS; RISK FACTORS; TIME FACTORS; VIRAL HEPATITIS VACCINES; WORLD HEALTH;

EID: 84888617736     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i44.7880     Document Type: Article

References (89)

1. Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis 2012; 12(Suppl 2): S2 [PMID: 23173556 DOI: 10.1186 /1471-2334-12-S2-S2]
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362 [PMID: 2523562 DOI: 10.1126/science.2523562]
3. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl 1): 74-81 [PMID: 19207969 DOI: 10.1111/j.1478-3231.2008.01934.x]
4. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]
5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]
6. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567 [PMID: 16122679 DOI: 10.1016/S1473-3099(05)70216-4]
7. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55 Suppl 1: S10-S15 [PMID: 22715208]
8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
9. Uhanova J, Tate RB, Tataryn DJ, Minuk GY. A population-based study of the epidemiology of hepatitis C in a North American population. J Hepatol 2012; 57: 736-742 [PMID: 22668641 DOI: 10.1016/j.jhep.2012.05.018]
10. Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 2008; 47: 1371-1383 [PMID: 18240152 DOI: 10.1002/hep.22127]
11. El-Karaksy H, Anwar GH, El-Raziky MS, El-Hawary M, Hashem M, El-Sayed R, El-Shabrawi M, Mohsen N, Fouad H, Esmat G. Anti-HCV prevalence among diabetic and nondiabetic Egyptian children. Curr Diabetes Rev 2010; 6: 388-392 [PMID: 20879976 DOI: 10.2174/157339910793499137]
12. Barakat SH, El-Bashir N. Hepatitis C virus infection among healthy Egyptian children: prevalence and risk factors. J Viral Hepat 2011; 18: 779-784 [PMID: 21992795 DOI: 10.1111/j.1365-2893.2010.01381.x]
13. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-891 [PMID: 10752705 DOI: 10.1016/S0140-6736(99)06527-7]
14. Hochmanan JA, Balistreri WF. Acute and chronic viral hepatitis. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. 3rd ed. New York: Cambridge University Press, 2007: 369-446 [DOI: 10.1017/CBO9780511547409.019]
15. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47 [PMID: 10847128 DOI: 10.1046/j.1365-2893.1999.6120139.x]
16. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-162 [PMID: 18022726 DOI: 10.1016/j.jhep.2007.07.033]
17. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010; 30: 342-355 [PMID: 20015149 DOI: 10.1111/j.1478-3231.2009.02188.x]
18. Pybus OG, Barnes E, Taggart R, Lemey P, Markov PV, Rasachak B, Syhavong B, Phetsouvanah R, Sheridan I, Humphreys IS, Lu L, Newton PN, Klenerman P. Genetic history of hepatitis C virus in East Asia. J Virol 2009; 83: 1071-1082 [PMID: 18971279 DOI: 10.1128/JVI.01501-08]
19. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010; 24: 1799-1812 [PMID: 20601854 DOI: 10.1097/QAD.0b013e32833c11a5]
20. Esmat G, Hashem M, El-Raziky M, El-Akel W, El-Naghy S, El-Koofy N, El-Sayed R, Ahmed R, Atta-Allah M, Hamid MA, El-Kamary SS, El-Karaksy H. Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. Liver Int 2012; 32: 449-456 [PMID: 22098096]
21. Okwen MP, Ngem BY, Alomba FA, Capo MV, Reid SR, Ewang EC. Uncovering high rates of unsafe injection equipment reuse in rural Cameroon: validation of a survey instrument that probes for specific misconceptions. Harm Reduct J 2011; 8: 4 [PMID: 21299899 DOI: 10.1186/1477-7517-8-4]
22. Hashem M, El-Karaksy H, Shata MT, Sobhy M, Helmy H, El-Naghi S, Galal G, Ali ZZ, Esmat G, Abdelwahab SF, Strickland GT, El-Kamary SS. Strong hepatitis C virus (HCV) specific cell-mediated immune responses in the absence of viremia or antibodies among uninfected siblings of HCV chronically infected children. J Infect Dis 2011; 203: 854-861 [PMID: 21257736 DOI: 10.1093/infdis/jiq123]
23. Bortolotti F, Resti M, Giacchino R, Crivellaro C, Zancan L, Azzari C, Gussetti N, Tasso L, Faggion S. Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children. J Pediatr 1998; 133: 378-381 [PMID: 9738720 DOI: 10.1016/S0022-3476(98)70273-2]
24. Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34: 223-229 [PMID: 11481604 DOI: 10.1053/jhep.2001.25885]
25. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, Rosenthal P, Schwarz KB. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012; 54: 838-855 [PMID: 22487950 DOI: 10.1097/MPG.0b013e318258328d]
26. Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C, Kako M, Ujiie N, Endo C, Matsui A. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330: 744-750 [PMID: 8107740 DOI: 10.1056/NEJM199403173301103]
27. Tajiri H, Miyoshi Y, Funada S, Etani Y, Abe J, Onodera T, Goto M, Funato M, Ida S, Noda C, Nakayama M, Okada S. Prospective study of mother-to-infant transmission of hepatitis C virus. Pediatr Infect Dis J 2001; 20: 10-14 [PMID: 11176560 DOI: 10.1097/00006454-200101000-00003]
28. Steininger C, Kundi M, Jatzko G, Kiss H, Lischka A, Holzmann H. Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis 2003; 187: 345-351 [PMID: 12552417 DOI: 10.1086/367704]
29. Murakami J, Nagata I, Iitsuka T, Okamoto M, Kaji S, Hoshika T, Matsuda R, Kanzaki S, Shiraki K, Suyama A, Hino S. Risk factors for mother-to-child transmission of hepatitis C virus: Maternal high viral load and fetal exposure in the birth canal. Hepatol Res 2012; 42: 648-657 [PMID: 22404371 DOI: 10.1111/j.1872-034X.2012.00968.x]
30. Minola E, Maccabruni A, Pacati I, Martinetti M. Amniocentesis as a possible risk factor for mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 33: 1341-1342 [PMID: 11343269 DOI: 10.1053/jhep.2001.0103305le02]
31. Ducarme G, Ceccaldi PF, Bernuau J, Luton D. Amniocentesis and viral risk (hepatitis B, C virus and HIV). J Gynecol Obstet Biol Reprod (Paris) 2009; 38: 469-473 [PMID: 19679409 DOI: 10.1016/j.jgyn.2009.07.001]
32. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, Alter MJ. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192: 1880-1889 [PMID: 16267758 DOI: 10.1086/497701]
33. European Paediatric Hepatitis C Virus Network. A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005; 192: 1872-1879 [PMID: 16267757 DOI: 10.1086/497695]
34. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology 2002; 36: S3-S20 [PMID: 12407572 DOI: 10.1053/jhep.2002.37117]
35. American Academy of Pediatrics. Hepatitis C. In: Pickering LK, editor. Redbook: 2003 report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2003: 336-340
36. Plunkett BA, Grobman WA. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol 2005; 192: 1153-1161 [PMID: 15846195 DOI: 10.1016/j.ajog.2004.10.600]
37. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol 2008; 49: 625-633 [PMID: 18706735 DOI: 10.1016/j.jhep.2008.07.005]
38. Jonas MM. Children with hepatitis C. Hepatology 2002; 36: S173-S178 [PMID: 12407591 DOI: 10.1002/hep.1840360722]
39. Wiegand J, Deterding K, Cornberg M, Wedemeyer H. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother 2008; 62: 860-865 [PMID: 18776191 DOI: 10.1093/jac/dkn346]
40. Vietri J, Prajapati G, El Khoury AC. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterol 2013; 13: 16 [PMID: 23324473 DOI: 10.1186/1471-230X-13-16]
41. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608 [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005]
42. González-Peralta RP, Langham MR, Andres JM, Mohan P, Colombani PM, Alford MK, Schwarz KB. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009; 48: 630-635 [PMID: 19412012 DOI: 10.1097/MPG.0b013e318170af04]
43. Strickland DK, Jenkins JJ, Hudson MM. Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer. J Pediatr Hematol Oncol 2001; 23: 527-529 [PMID: 11878782 DOI: 10.1097/00043426-200111000-00012]
44. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-148 [PMID: 18848939 DOI: 10.1053/j.gastro.2008.09.014]
45. Madhoun MF, Fazili J, Bright BC, Bader T, Roberts DN, Bronze MS. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis. Am J Med Sci 2010; 339: 169-173 [PMID: 20087166 DOI: 10.1097/MAJ.0b013e3181c4af27]
46. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26: 401-412 [PMID: 23199500 DOI: 10.1016/j.bpg.2012.09.009]
47. Rumbo C, Fawaz RL, Emre SH, Suchy FJ, Kerkar N, Morotti RA, Shneider BL. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr 2006; 43: 209-216 [PMID: 16877987 DOI: 10.1097/01. mpg.0000228117.52229.32]
48. Badizadegan K, Jonas MM, Ott MJ, Nelson SP, Perez-Atayde AR. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998; 28: 1416-1423 [PMID: 9794930 DOI: 10.1002/hep.510280534]
49. Kage M, Fujisawa T, Shiraki K, Tanaka T, Fujisawa T, Kimura A, Shimamatsu K, Nakashima E, Kojiro M, Koike M, Tazawa Y, Abukawa D, Okaniwa M, Takita H, Matsui A, Hayashi T, Etou T, Terasawa S, Sugiyama K, Tajiri H, Yoden A, Kajiwara Y, Sata M, Uchimura Y. Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan. Hepatology 1997; 26: 771-775 [PMID: 9303511 DOI: 10.1002/hep.510260333]
50. Lai ME, De Virgilis S, Argiolu F, Farci P, Mazzoleni AP, Lisci V, Rapicetta M, Clemente MG, Nurchis P, Arnone M. Evaluation of antibodies to hepatitis C virus in a long-term prospective study of posttransfusion hepatitis among thalassemic children: comparison between firstand second-generation assay. J Pediatr Gastroenterol Nutr 1993; 16: 458-464 [PMID: 7686220 DOI: 10.1097/00005176-199305000-00020]
51. Bortolotti F, Vajro P, Cadrobbi P, Lepore L, Zancan L, Barbera C, Crivellaro C, Fontanella A, Alberti A, D'Addezio M. Cryptogenic chronic liver disease and hepatitis C virus infection in children. J Hepatol 1992; 15: 73-76 [PMID: 1324275 DOI: 10.1016/0168-8278(92)90014-G]
52. Inui A, Fujisawa T, Miyagawa Y, Sekine I, Hanada R, Yamamoto K, Shiihara H, Inui M. Histologic activity of the liver in children with transfusion-associated chronic hepatitis C. J Hepatol 1994; 21: 748-753 [PMID: 7890889 DOI: 10.1016/S0168-8278(94)80234-3]
53. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 39: 2-17 [PMID: 16884964 DOI: 10.1016/j.dld.2006.06.008]
54. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol 2002; 55: 4-13 [PMID: 11825916 DOI: 10.1136/jcp.55.1.4]
55. Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, Puccini R, Michelassi C, Zignego AL. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33: 355-374 [PMID: 15190522 DOI: 10.1016/j.se marthrit.2003.10.001]
56. Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schüler A, Ennen JC, Ahl B, Manns MP, Böker KW. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: 845-851 [PMID: 15519659 DOI: 10.1016/j.jhep.2004.07.022]
57. Bokemeyer M, Ding XQ, Goldbecker A, Raab P, Heeren M, Arvanitis D, Tillmann HL, Lanfermann H, Weissenborn K. Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy. Gut 2011; 60: 370-377 [PMID: 20926642 DOI: 10.1136/gut.2010.217976]
58. Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, Murray KF, Narkewicz MR, Rosenthal P, Smith LJ, Schwarz KB, Robuck P, Barton B, González-Peralta RP. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009; 48: 341-347 [PMID: 19242286 DOI: 10.1097/MPG.0b013e318185998f]
59. Nydegger A, Srivastava A, Wake M, Smith AL, Hardikar W. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol 2008; 23: 226-230 [PMID: 18289357 DOI: 10.1111/j.1440-1746.2007.04859.x]
60. Menzin J, White LA, Nichols C, Deniz B. The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective. BMC Health Serv Res 2012; 12: 459 [PMID: 23241078 DOI: 10.1186/1472-6963-1 2-459]
61. Jhaveri R, Grant W, Kauf TL, McHutchison J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr 2006; 148: 353-358 [PMID: 16615966]
62. Mohan N, Kamsakul W, Wirth S, Fujisawa T, D'Agostino D. Hepatitis B and C: Report of the FISPGHAN Working Group. J Pediatr Gastroenterol Nutr 2012; 55: 631-635 [PMID: 22983375]
63. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011; 54: 1273-1285 [PMID: 21236312 DOI: 10.1016/j.jhep.2010.09.040]
64. El-Kamary SS, Hashem M, Saleh DA, Abdelwahab SF, Sobhy M, Shebl FM, Shardell MD, Strickland GT, Shata MT. Hepatitis C virus-specific cell-mediated immune responses in children born to mothers infected with hepatitis C virus. J Pediatr 2013; 162: 148-154 [PMID: 22883419]
65. Hatzakis A, Van Damme P, Alcorn K, Gore C, Benazzouz M, Berkane S, Buti M, Carballo M, Cortes Martins H, Deuffic-Burban S, Dominguez A, Donoghoe M, Elzouki AN, Ben-Alaya Bouafif N, Esmat G, Esteban R, Fabri M, Fenton K, Goldberg D, Goulis I, Hadjichristodoulou C, Hatzigeorgiou T, Hamouda O, Hasurdjiev S, Hughes S, Kautz A, Malik M, Manolakopoulos S, Matičič M, Papatheodoridis G, Peck R, Peterle A, Potamitis G, Prati D, Roudot-Thoraval F, Reic T, Sharara A, Shennak M, Shiha G, Shouval D, Sočan M, Thomas H, Thursz M, Tosti M, Trépo C, Vince A, Vounou E, Wiessing L, Manns M. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat 2013; 20 Suppl 2: 1-20 [PMID: 23827008 DOI: 10.1111/jvh.12120]
66. Clark PJ, Muir AJ. Overcoming barriers to care for hepatitis C. N Engl J Med 2012; 366: 2436-2438 [PMID: 22738095 DOI: 10.1056/NEJMp1202608]
67. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, Poordad F, Afdhal N, Zeuzem S, Piratvisuth T, Marcellin P, Fried MW. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 2013; 57: 1325-1332 [PMID: 23315914]
68. Sublette VA, Douglas MW, McCaffery K, George J, Perry KN. Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review. Liver Int 2013; 33: 894-903 [PMID: 23581550 DOI: 10.1111/liv.12138]
69. Martel-Laferrière V, Dieterich DT. Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR. Clin Liver Dis 2013; 17: 93-103 [PMID: 23177285 DOI: 10.1016/j.cld.2012.09.001]
70. Alexopoulou A, Papatheodoridis GV. Current progress in the treatment of chronic hepatitis C. World J Gastroenterol 2012; 18: 6060-6069 [PMID: 23155334]
71. Di Marco V. Chronic hepatitis C in children is a mild and curable liver disease. Dig Liver Dis 2011; 43: 266-267 [PMID: 21353653 DOI: 10.1016/j.dld.2011.02.005]
72. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012; 18: 99-104 [PMID: 22253515 DOI: 10.3748/wjg.v18.i2.99]
73. Pol S, Roberts SK, Andreone P, Younossi Z, Diago M, Lawitz EJ, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, DeMasi R, van Heeswijk R, De Meyer S, Picchio G, Witek J, Zeuzem S. Efficacy and safety of telaprevir based regimens in cirrhotic patients with hcv genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE phase III study. Hepatology 2011; 54 (Suppl 1): 374A-375A
74. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224 [PMID: 22256805]
75. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53 [PMID: 23281975]
76. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44 [PMID: 23281974]
77. Zeuzem S, Asselah T, Angus PW, Zarski JH, Larrey DG, Mullhaupt B, Gane EJ, Schuchmann M, Lohse AW, Pol S, Moussalli J, Bronowicki J, Roberts SK, Arasteh K, Zoulim F, Stern JO, Mensa FJ, Nehmiz G. High sustained virologic response following interferon-free treatment of chronic HCV Gt1 infection for 4 wk with HCV protease inhibitor BI201335, polymerase inhibitor BI207127 and ribavirin, followed by BI201335 and PegIFN/Ribavirin-the SOUND-C1 study. Hepatology 2011; 54: 486A-487A
78. Sulkowski M, Rodriguez-Torres M, Lawitz E, Shiffman M, Pol S, Herring R, McHutchison J, Pang P, Brainard D, Wyles D, Habersetzer F. High sustained virologic response rate in treatment-naive HCV genotype 1A and 1B patients treated for 12 wk with an interferon-free all-oral quad regimen: interim results. J Hepatol 2012; 56: S560
79. Gane EJ, Pockros P, Zeuzem S, Marcellin P, Shikhman A, Bernaards C, Yetzer ES, Shulman N, Tong X, Najera I, Bertasso A, Hammond J, Stancic S. Interferon-free treatment with a combination of Mericitabine and Danoprevir/r with or without Ribavirin in treatment-naive HCV genotype 1-infected patients. J Hepatol 2012; 56: S555-S556
80. Halfon P, Bourliere M, Ouzan D, Maor Y, Renou C, Wartelle C, Pénaranda G, Tran A, Botta D, Oules V, Castellani P, Portal I, Argiro L, Dessein A. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. Eur J Gastroenterol Hepatol 2011; 23: 931-935
81. Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 2011; 6: e18322 [PMID: 21479134]
82. Kurbanov F, Abdel-Hamid M, Latanich R, Astemborski J, Mohamed M, Mikhail NM, El-Daly M, El-Kafrawy S, Thomas DL, Thio CL. Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort. J Infect Dis 2011; 204: 1391-1394 [PMID: 21933876]
83. Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 2013; 11: 6 [PMID: 23298311]
84. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Li YN, Wu MS, Dai CY, Juo SH, Chuang WL. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13 [PMID: 21254157]
85. Holmes JA, Desmond PV, Thompson AJ. Redefining base-line demographics: the role of genetic testing in hepatitis C virus infection. Clin Liver Dis 2011; 15: 497-513 [PMID: 21867933]
86. Ruiz-Extremera A, Muñoz-Gámez JA, Salmerón-Ruiz MA, de Rueda PM, Quiles-Pérez R, Gila-Medina A, Casado J, Belén Martín A, Sanjuan-Nuñez L, Carazo A, Pavón EJ, Ocete-Hita E, León J, Salmerón J. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011; 53: 1830-1838 [PMID: 21413051]
87. Shaker OG, Nassar YH, Nour ZA, El Raziky M. Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children. J Pediatr Gastroenterol Nutr 2013; 57: 155-160 [PMID: 23880623 DOI: 10.1097/MPG.0b013e31828febf0]
88. Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, Rutter K, Staettermayer AF, Datz C, Scherzer TM, Strassl R, Bischof M, Stauber R, Bodlaj G, Laferl H, Holzmann H, Steindl-Munda P, Ferenci P, Hofer H. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 2012; 142: 78-85.e2 [PMID: 22192885 DOI: 10.1053/j.gastro.2011.09.039]
89. Shaker O, El-Shehaby A, Fayez S, Zahra A, Marzouk S, El Raziky M. Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4. Cell Biochem Funct 2013; 31: 620-625 [PMID: 23400862 DOI: 10.1002/cbf.2954]